A. Kato

Dose‐dependent Intestinal and Hepatic First‐pass Metabolism of Midazolam, a Cytochrome P450 3A Substrate with Differently Modulated Enzyme Activity in Rats

T. Murakami, M. Takano, F. Higashikawa, 1999, The Journal of pharmacy and pharmacology.

Urinary excretion characteristics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate.

M. Hashida, Y. Takakura, A. Arimoto, 1985, Journal of pharmacobio-dynamics.

Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine.

M. Fukushima, H. Okuda, T. Nishiyama, 1998, Cancer letters.

Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.

M. Hashida, N. Tanigawa, S. Muranishi, 1981, Gan.

Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide

N. Aoki, Y. Sakata, Satoko Nakamura, 1988, British journal of haematology.

A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.

H. Okuda, T Watabe, K Ogura, 1998, The Journal of pharmacology and experimental therapeutics.

Physico-chemical and antitumor characteristics of high molecular weight prodrugs of mitomycin C.

M. Hashida, Y. Takakura, H. Sezaki, 1982, Chemical & pharmaceutical bulletin.

Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.

M. Hashida, Y. Takakura, H. Sezaki, 1984, Drug metabolism and disposition: the biological fate of chemicals.

First-pass metabolism of ONO-5046 (N-[2-[4-(2,2-dimethylpropionyloxy) phenylsulfonylamino]benzoyl]aminoacetic acid), a novel elastase inhibitor, in rats.

T. Murakami, N. Yata, Y. Higashi, 1997, Biological & pharmaceutical bulletin.